

Jennifer K Quint

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7252276/publications.pdf>

Version: 2024-02-01

224
papers

6,970
citations

70961

41
h-index

82410

72
g-index

246
all docs

246
docs citations

246
times ranked

9394
citing authors

#	ARTICLE	IF	CITATIONS
1	Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. <i>European Respiratory Journal</i> , 2016, 47, 186-193.	3.1	393
2	Defective macrophage phagocytosis of bacteria in COPD. <i>European Respiratory Journal</i> , 2010, 35, 1039-1047.	3.1	301
3	Temporal Clustering of Exacerbations in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 369-374.	2.5	231
4	Indirect acute effects of the COVID-19 pandemic on physical and mental health in the UK: a population-based study. <i>The Lancet Digital Health</i> , 2021, 3, e217-e230.	5.9	220
5	Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. <i>Lancet Respiratory Medicine</i> , 2020, 8, 1106-1120.	5.2	211
6	Validation of chronic obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD). <i>BMJ Open</i> , 2014, 4, e005540-e005540.	0.8	203
7	Defining the relationship between COPD and CVD: what are the implications for clinical practice?. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346581775052.	1.0	186
8	Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1656-1665.	2.5	171
9	The neutrophil in chronic obstructive pulmonary disease. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 119, 1065-1071.	1.5	143
10	Relationship between depression and exacerbations in COPD. <i>European Respiratory Journal</i> , 2008, 32, 53-60.	3.1	142
11	Incidence of Community-Acquired Lower Respiratory Tract Infections and Pneumonia among Older Adults in the United Kingdom: A Population-Based Study. <i>PLoS ONE</i> , 2013, 8, e75131.	1.1	137
12	Exacerbation risk and characterisation of the UK's asthma population from infants to old age. <i>Thorax</i> , 2018, 73, 313-320.	2.7	123
13	Natural History of Chronic Obstructive Pulmonary Disease Exacerbations in a General Practice-based Population with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 464-471.	2.5	122
14	Validation of the Recording of Acute Exacerbations of COPD in UK Primary Care Electronic Healthcare Records. <i>PLoS ONE</i> , 2016, 11, e0151357.	1.1	117
15	Determinants and impact of fatigue in patients with chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2009, 103, 216-223.	1.3	107
16	Current smoking and COVID-19 risk: results from a population symptom app in over 2.4 million people. <i>Thorax</i> , 2021, 76, 714-722.	2.7	105
17	Serum IP-10 as a Biomarker of Human Rhinovirus Infection at Exacerbation of COPD. <i>Chest</i> , 2010, 137, 812-822.	0.4	101
18	Risk factors for acute exacerbations of COPD in a primary care population: a retrospective observational cohort study. <i>BMJ Open</i> , 2014, 4, e006171.	0.8	97

#	ARTICLE	IF	CITATIONS
19	Respiratory Syncytial Virus Persistence in Chronic Obstructive Pulmonary Disease. <i>Pediatric Infectious Disease Journal</i> , 2008, 27, S63-S70.	1.1	84
20	SABINA: An Overview of Short-Acting \hat{I}^{22} -Agonist Use in Asthma in European Countries. <i>Advances in Therapy</i> , 2020, 37, 1124-1135.	1.3	84
21	The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1467-1478.	5.2	84
22	Domiciliary pulse-oximetry at exacerbation of chronic obstructive pulmonary disease: prospective pilot study. <i>BMC Pulmonary Medicine</i> , 2010, 10, 52.	0.8	78
23	Validation of asthma recording in the Clinical Practice Research Datalink (CPRD). <i>BMJ Open</i> , 2017, 7, e017474.	0.8	76
24	Improved aerosol correction for OMI tropospheric NO ₂ retrieval over East Asia: constraint from CALIOP aerosol vertical profile. <i>Atmospheric Measurement Techniques</i> , 2019, 12, 1-21.	1.2	75
25	Characterising low-cost sensors in highly portable platforms to quantify personal exposure in diverse environments. <i>Atmospheric Measurement Techniques</i> , 2019, 12, 4643-4657.	1.2	74
26	Cardiotoxicity during Invasive Pneumococcal Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 739-745.	2.5	70
27	Predictive accuracy of patient-reported exacerbation frequency in COPD. <i>European Respiratory Journal</i> , 2011, 37, 501-507.	3.1	69
28	Impact of COVID-19 national lockdown on asthma exacerbations: interrupted time-series analysis of English primary care data. <i>Thorax</i> , 2021, 76, 860-866.	2.7	69
29	Non-communicable diseases in sub-Saharan Africa: a scoping review of large cohort studies. <i>Journal of Global Health</i> , 2019, 9, 020409.	1.2	68
30	Risk of myocardial infarction (MI) and death following MI in people with chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. <i>BMJ Open</i> , 2015, 5, e007824.	0.8	66
31	Low uptake of palliative care for COPD patients within primary care in the UK. <i>European Respiratory Journal</i> , 2018, 51, 1701879.	3.1	66
32	Asthma-Related Health Outcomes Associated with Short-Acting \hat{I}^{22} -Agonist Inhaler Use: An Observational UK Study as Part of the SABINA Global Program. <i>Advances in Therapy</i> , 2020, 37, 4190-4208.	1.3	66
33	Recording of hospitalizations for acute exacerbations of COPD in UK electronic health care records. <i>Clinical Epidemiology</i> , 2016, Volume 8, 771-782.	1.5	65
34	Exacerbation Patterns in Adults with Asthma in England. A Population-based Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 446-453.	2.5	63
35	Closing the mortality gap after a myocardial infarction in people with and without chronic obstructive pulmonary disease. <i>Heart</i> , 2015, 101, 1103-1110.	1.2	61
36	Pulmonary Rehabilitation as a Mechanism to Reduce Hospitalizations for Acute Exacerbations of COPD. <i>Chest</i> , 2016, 150, 837-859.	0.4	60

#	ARTICLE	IF	CITATIONS
37	Bronchiectasis and the risk of cardiovascular disease: a population-based study. <i>Thorax</i> , 2017, 72, 161-166.	2.7	60
38	The Impact of the COVID-19 Pandemic on the Uptake of Influenza Vaccine: UK-Wide Observational Study. <i>JMIR Public Health and Surveillance</i> , 2021, 7, e26734.	1.2	56
39	Myocardial Infarction and Ischemic Stroke after Exacerbations of Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , 2018, 15, 935-946.	1.5	52
40	Patient symptoms and experience following COVID-19: results from a UK-wide survey. <i>BMJ Open Respiratory Research</i> , 2021, 8, e001075.	1.2	51
41	Changing prevalence of current asthma and inhaled corticosteroid treatment in the UK: population-based cohort 2006-2016. <i>European Respiratory Journal</i> , 2019, 53, 1802130.	3.1	50
42	25-hydroxyvitamin D deficiency, exacerbation frequency and human rhinovirus exacerbations in chronic obstructive pulmonary disease. <i>BMC Pulmonary Medicine</i> , 2012, 12, 28.	0.8	47
43	Global Associations between Air Pollutants and Chronic Obstructive Pulmonary Disease Hospitalizations: A Systematic Review. <i>Annals of the American Thoracic Society</i> , 2016, 13, 1814-1827.	1.5	43
44	Validity and interpretation of spirometric recordings to diagnose COPD in UK primary care. <i>International Journal of COPD</i> , 2017, Volume 12, 1663-1668.	0.9	41
45	Risk factors for hospital admission in the 28 days following a community-acquired pneumonia diagnosis in older adults, and their contribution to increasing hospitalisation rates over time: a cohort study. <i>BMJ Open</i> , 2015, 5, e008737.	0.8	40
46	Know Your Heart: Rationale, design and conduct of a cross-sectional study of cardiovascular structure, function and risk factors in 4500 men and women aged 35-69 years from two Russian cities, 2015-18. <i>Wellcome Open Research</i> , 2018, 3, 67.	0.9	40
47	Acute kidney injury in stable COPD and at exacerbation. <i>International Journal of COPD</i> , 2015, 10, 2067.	0.9	38
48	Oral corticosteroid prescription patterns for asthma in France, Germany, Italy and the UK. <i>European Respiratory Journal</i> , 2020, 55, 1902363.	3.1	38
49	Prognostic variables and scores identifying the end of life in COPD: a systematic review. <i>International Journal of COPD</i> , 2017, Volume 12, 2239-2256.	0.9	36
50	Temporal trends in the incidence, treatment patterns, and outcomes of coronary artery disease and peripheral artery disease in the UK, 2006-2015. <i>European Heart Journal</i> , 2020, 41, 1636-1649.	1.0	36
51	GP consultation rates for sequelae after acute covid-19 in patients managed in the community or hospital in the UK: population based study. <i>BMJ</i> , 2021, 375, e065834.	3.0	36
52	Short-Acting Beta-2-Agonist Exposure and Severe Asthma Exacerbations: SABINA Findings From Europe and North America. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 2297-2309.e10.	2.0	35
53	Building toolkits for COPD exacerbations: lessons from the past and present. <i>Thorax</i> , 2019, 74, 898-905.	2.7	34
54	Increased Mortality Risk in Patients With Primary and Secondary Adrenal Insufficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e2759-e2768.	1.8	34

#	ARTICLE	IF	CITATIONS
55	Risk Predictors and Symptom Features of Long COVID Within a Broad Primary Care Patient Population Including Both Tested and Untested Patients. <i>Journal of Pragmatic and Observational Research</i> , 2021, Volume 12, 93-104.	1.1	32
56	Previously undiagnosed obesity hypoventilation syndrome. <i>Thorax</i> , 2007, 62, 462-463.	2.7	31
57	Improved incidence estimates from linked vs. stand-alone electronic health records. <i>Journal of Clinical Epidemiology</i> , 2016, 75, 66-69.	2.4	31
58	Effects of Pulmonary Rehabilitation on Exacerbation Number and Severity in People With COPD. <i>Chest</i> , 2017, 152, 1188-1202.	0.4	31
59	Validation of asthma recording in electronic health records: a systematic review. <i>Clinical Epidemiology</i> , 2017, Volume 9, 643-656.	1.5	31
60	Concomitant diagnosis of asthma and COPD: a quantitative study in UK primary care. <i>British Journal of General Practice</i> , 2018, 68, e775-e782.	0.7	31
61	Burden of preschool wheeze and progression to asthma in the UK: Population-based cohort 2007 to 2017. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1949-1958.	1.5	30
62	Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison. <i>Respiratory Research</i> , 2021, 22, 64.	1.4	29
63	Know Your Heart: Rationale, design and conduct of a cross-sectional study of cardiovascular structure, function and risk factors in 4500 men and women aged 35-69 years from two Russian cities, 2015-18. <i>Wellcome Open Research</i> , 2018, 3, 67.	0.9	29
64	Frequency and Severity of Exacerbations of COPD Associated with Future Risk of Exacerbations and Mortality: A UK Routine Health Care Data Study. <i>International Journal of COPD</i> , 2022, Volume 17, 427-437.	0.9	29
65	Hospitalisation and mortality in patients with comorbid COPD and heart failure: a systematic review and meta-analysis. <i>Respiratory Research</i> , 2020, 21, 54.	1.4	28
66	Research priorities for exacerbations of COPD. <i>Lancet Respiratory Medicine</i> , 2021, 9, 824-826.	5.2	28
67	Changes in COPD inhaler prescriptions in the United Kingdom, 2000 to 2016. <i>International Journal of COPD</i> , 2019, Volume 14, 279-287.	0.9	27
68	Belief of having had unconfirmed Covid-19 infection reduces willingness to participate in app-based contact tracing. <i>Npj Digital Medicine</i> , 2020, 3, 146.	5.7	27
69	Changing causes of death for patients with chronic respiratory disease in England, 2005-2015. <i>Thorax</i> , 2019, 74, 483-491.	2.7	26
70	Relationship between asthma and severe COVID-19: a national cohort study. <i>Thorax</i> , 2023, 78, 120-127.	2.7	26
71	Epidemiology of bronchiectasis in the UK: Findings from the British lung foundation's Respiratory health of the nation project. <i>Respiratory Medicine</i> , 2019, 158, 21-23.	1.3	25
72	Air Pollution Monitoring for Health Research and Patient Care. An Official American Thoracic Society Workshop Report. <i>Annals of the American Thoracic Society</i> , 2019, 16, 1207-1214.	1.5	25

#	ARTICLE	IF	CITATIONS
73	How to validate a diagnosis recorded in electronic health records. <i>Breathe</i> , 2019, 15, 64-68.	0.6	25
74	UK prevalence of underlying conditions which increase the risk of severe COVID-19 disease: a point prevalence study using electronic health records. <i>BMC Public Health</i> , 2021, 21, 484.	1.2	25
75	External validation of ADO, DOSE, COTE and CODEX at predicting death in primary care patients with COPD using standard and machine learning approaches. <i>Respiratory Medicine</i> , 2018, 138, 150-155.	1.3	24
76	The REal Life EVIDence Assessment Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies. <i>Clinical and Translational Allergy</i> , 2019, 9, 21.	1.4	24
77	<p>Predictors of Referral to Pulmonary Rehabilitation from UK Primary Care</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 2941-2952.	0.9	24
78	Accelerated FEV₁ decline and risk of cardiovascular disease and mortality in a primary care population of COPD patients. <i>European Respiratory Journal</i> , 2021, 57, 2000918.	3.1	24
79	Cardiovascular Outcomes after a Respiratory Tract Infection among Adults with Non"Cystic Fibrosis Bronchiectasis: A General Population"-based Study. <i>Annals of the American Thoracic Society</i> , 2018, 15, 315-321.	1.5	23
80	Realising the full potential of data-enabled trials in the UK: a call for action. <i>BMJ Open</i> , 2021, 11, e043906.	0.8	23
81	Pulmonary rehabilitation and severe exacerbations of COPD: solution or white elephant?. <i>ERJ Open Research</i> , 2015, 1, 00050-2015.	1.1	22
82	Cost saving of switching to equivalent inhalers and its effect on health outcomes. <i>Thorax</i> , 2019, 74, 1078-1086.	2.7	22
83	Patterns of breathlessness and associated consulting behaviour: results of an online survey. <i>Thorax</i> , 2019, 74, 814-817.	2.7	22
84	Chronic Obstructive Pulmonary Disease and the Risk of Stroke. <i>Annals of the American Thoracic Society</i> , 2017, 14, 754-765.	1.5	21
85	Chronic obstructive pulmonary disease and the risk of 12 cardiovascular diseases: a population-based study using UK primary care data. <i>Thorax</i> , 2018, 73, 877-879.	2.7	21
86	Validation of U.S. mortality prediction models for hospitalized heart failure in the United Kingdom and Japan. <i>European Journal of Heart Failure</i> , 2018, 20, 1179-1190.	2.9	21
87	Frailty in COPD: an analysis of prevalence and clinical impact using UK Biobank. <i>BMJ Open Respiratory Research</i> , 2022, 9, e001314.	1.2	21
88	Quality standards in respiratory real-life effectiveness research: the REal Life EVIDence Assessment Tool (RELEVANT): report from the Respiratory Effectiveness Group"European Academy of Allergy and Clinical Immunology Task Force. <i>Clinical and Translational Allergy</i> , 2019, 9, 20.	1.4	20
89	Paediatric and adult bronchiectasis: Diagnosis, disease burden and prognosis. <i>Respirology</i> , 2019, 24, 413-422.	1.3	20
90	Personal exposure to air pollution and respiratory health of COPD patients in London. <i>European Respiratory Journal</i> , 2021, 58, 2003432.	3.1	20

#	ARTICLE	IF	CITATIONS
91	Risk factors and secondary care utilisation in a primary care population with non-tuberculous mycobacterial disease in the UK. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019, 38, 117-124.	1.3	19
92	Health and cost impact of stepping down asthma medication for UK patients, 2001â€“2017: A population-based observational study. <i>PLoS Medicine</i> , 2020, 17, e1003145.	3.9	19
93	A Pandemic Lesson for Global Lung Diseases: Exacerbations Are Preventable. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 1271-1280.	2.5	19
94	Use and utility of a 24-hour Telephone Support Service for â€“high riskâ€™ patients with COPD. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2010, 19, 260-265.	2.5	18
95	Chronic obstructive pulmonary disease and acute myocardial infarction: effects on presentation, management, and outcomes. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2016, 2, 81-90.	1.8	18
96	Asthma and treatment with inhaled corticosteroids: associations with hospitalisations with pneumonia. <i>BMC Pulmonary Medicine</i> , 2019, 19, 254.	0.8	18
97	Standardisation of Clinical Assessment, Management and Follow-Up of Acute Hospitalised Exacerbation of COPD: A Europe-Wide Consensus. <i>International Journal of COPD</i> , 2021, Volume 16, 321-332.	0.9	18
98	Impact of COVID-19 pandemic on asthma exacerbations: Retrospective cohort study of over 500,000 patients in a national English primary care database. <i>Lancet Regional Health - Europe</i> , The, 2022, 19, 100428.	3.0	18
99	COPD disease severity and the risk of venous thromboembolic events: a matched case–control study. <i>International Journal of COPD</i> , 2016, 11, 899.	0.9	17
100	Linking e-health records, patient-reported symptoms and environmental exposure data to characterise and model COPD exacerbations: protocol for the COPE study. <i>BMJ Open</i> , 2016, 6, e011330.	0.8	17
101	Know Your Heart: Rationale, design and conduct of a cross-sectional study of cardiovascular structure, function and risk factors in 4500 men and women aged 35-69 years from two Russian cities, 2015-18. <i>Wellcome Open Research</i> , 0, 3, 67.	0.9	17
102	Nontuberculous mycobacterial disease managed within UK primary care, 2006â€“2016. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 1795-1803.	1.3	16
103	Understanding the relationships between environmental factors and exacerbations of COPD. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 39-50.	1.0	16
104	Joint patient and clinician priority setting to identify 10 key research questions regarding the long-term sequelae of COVID-19. <i>Thorax</i> , 2022, 77, 717-720.	2.7	16
105	Prescribing Pathways to Triple Therapy: A Multi-Country, Retrospective Observational Study of Adult Patients with Chronic Obstructive Pulmonary Disease. <i>Pulmonary Therapy</i> , 2020, 6, 333-350.	1.1	15
106	National clinical audit for hospitalised exacerbations of COPD. <i>ERJ Open Research</i> , 2020, 6, 00208-2020.	1.1	15
107	<p>Characteristics Associated with Accelerated Lung Function Decline in a Primary Care Population with Chronic Obstructive Pulmonary Disease</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 3079-3091.	0.9	15
108	Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study. <i>Respiratory Research</i> , 2021, 22, 25.	1.4	15

#	ARTICLE	IF	CITATIONS
109	Incidence of type II diabetes in chronic obstructive pulmonary disease: a nested case-control study. <i>Npj Primary Care Respiratory Medicine</i> , 2019, 29, 28.	1.1	14
110	Inhaled corticosteroids, blood eosinophils, and FEV ₁ decline in patients with COPD in a large UK primary health care setting. <i>International Journal of COPD</i> , 2019, Volume 14, 1063-1073.	0.9	14
111	Impact of chronic obstructive pulmonary disease on readmission after hospitalization for acute heart failure: A nationally representative US cohort study. <i>International Journal of Cardiology</i> , 2019, 290, 113-118.	0.8	14
112	Completeness and validity of alcohol recording in general practice within the UK: a cross-sectional study. <i>BMJ Open</i> , 2019, 9, e031537.	0.8	14
113	Do influenza and pneumococcal vaccines prevent community-acquired respiratory infections among older people with diabetes and does this vary by chronic kidney disease? A cohort study using electronic health records. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000332.	1.2	14
114	Is vitamin D deficiency important in the natural history of COPD?. <i>Thorax</i> , 2010, 65, 192-194.	2.7	13
115	Eligibility for Lung Volume Reduction Surgery in Patients With COPD Identified in a UK Primary Care Setting. <i>Chest</i> , 2020, 157, 276-285.	0.4	13
116	Impact of a functional polymorphism in the PAR-1 gene promoter in COPD and COPD exacerbations. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2014, 307, L311-L316.	1.3	12
117	Relationship between heart failure and the risk of acute exacerbation of COPD. <i>Thorax</i> , 2021, 76, 807-814.	2.7	12
118	Mechanisms Underlying the Association of Chronic Obstructive Pulmonary Disease With Heart Failure. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1963-1973.	2.3	12
119	Environmental Sustainability in Respiratory Care: An Overview of the healthCARE-Based environmental Cost of Treatment (CARBON) Programme. <i>Advances in Therapy</i> , 2022, 39, 2270-2280.	1.3	12
120	Diagnosis of acute kidney injury and its association with in-hospital mortality in patients with infective exacerbations of bronchiectasis: cohort study from a UK nationwide database. <i>BMC Pulmonary Medicine</i> , 2016, 16, 14.	0.8	11
121	Temporal Trends in the Incidence of Heart Failure among Patients with Chronic Obstructive Pulmonary Disease and Its Association with Mortality. <i>Annals of the American Thoracic Society</i> , 2020, 17, 939-948.	1.5	11
122	Real world effects of COPD medications: a cohort study with validation against results from randomised controlled trials. <i>European Respiratory Journal</i> , 2021, 57, 2001586.	3.1	11
123	Cardiovascular Disease in Patients With Primary and Secondary Adrenal Insufficiency and the Role of Comorbidities. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1284-1293.	1.8	11
124	Hospitalization for Heart Failure in the United States, UK, Taiwan, and Japan: An International Comparison of Administrative Health Records on 413,385 Individual Patients. <i>Journal of Cardiac Failure</i> , 2022, 28, 353-366.	0.7	11
125	Variation in global COVID-19 symptoms by geography and by chronic disease: A global survey using the COVID-19 Symptom Mapper. <i>EClinicalMedicine</i> , 2022, 45, 101317.	3.2	11
126	Predicting mortality after acute coronary syndromes in people with chronic obstructive pulmonary disease. <i>Heart</i> , 2016, 102, 1442-1448.	1.2	10

#	ARTICLE	IF	CITATIONS
127	Mortality after admission for heart failure in the UK compared with Japan. <i>Open Heart</i> , 2018, 5, e000811.	0.9	10
128	<p>Inhaled Corticosteroid Treatment Regimens and Health Outcomes in a UK COPD Population Study</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 701-710.	0.9	10
129	SERPINA1 11478G->A variant, serum $\hat{A}1$ -antitrypsin, exacerbation frequency and FEV1 decline in COPD. <i>Thorax</i> , 2011, 66, 418-424.	2.7	9
130	Recruitment of patients with Chronic Obstructive Pulmonary Disease (COPD) from the Clinical Practice Research Datalink (CPRD) for research. <i>Npj Primary Care Respiratory Medicine</i> , 2018, 28, 21.	1.1	9
131	The WISDOM of inhaled corticosteroids in COPD. <i>Thorax</i> , 2014, 69, 1071-1072.	2.7	8
132	Cardiovascular disease in COPD: time to quash a silent killer. <i>Lancet Respiratory Medicine</i> , the, 2016, 4, 687-689.	5.2	8
133	Validation of asthma recording in electronic health records: protocol for a systematic review. <i>BMJ Open</i> , 2017, 7, e014694.	0.8	8
134	Inhaled corticosteroids and FEV1 decline in chronic obstructive pulmonary disease: a systematic review. <i>Respiratory Research</i> , 2019, 20, 277.	1.4	8
135	Lung volume reduction eligibility in patients with COPD completing pulmonary rehabilitation: results from the UK National Asthma and COPD Audit Programme. <i>BMJ Open</i> , 2020, 10, e040942.	0.8	8
136	Predictors of pulmonary rehabilitation completion in the UK. <i>ERJ Open Research</i> , 2021, 7, 00509-2020.	1.1	8
137	A semi-supervised approach for rapidly creating clinical biomarker phenotypes in the UK Biobank using different primary care EHR and clinical terminology systems. <i>JAMIA Open</i> , 2021, 3, 545-556.	1.0	8
138	Differences in Outcomes between Heart Failure Phenotypes in Patients with Coexistent Chronic Obstructive Pulmonary Disease: A Cohort Study. <i>Annals of the American Thoracic Society</i> , 2022, 19, 971-980.	1.5	8
139	Chronic obstructive pulmonary disease and the risk of stroke: a systematic review protocol. <i>BMJ Open</i> , 2016, 6, e011898.	0.8	7
140	Trends in mortality from respiratory system diseases in Greece during the financial crisis. <i>European Respiratory Journal</i> , 2016, 48, 1487-1489.	3.1	7
141	Presentation, management and mortality after a first MI in people with and without asthma: A study using UK MINAP data. <i>Chronic Respiratory Disease</i> , 2018, 15, 60-70.	1.0	7
142	Effectiveness and Safety of COPD Maintenance Therapy with $\hat{A}T$ iotropium/Olodaterol versus LABA/ICS in a US Claims Database. <i>Advances in Therapy</i> , 2021, 38, 2249-2270.	1.3	7
143	Determinants of Shielding Behavior During the COVID-19 Pandemic and Associations With Well-being Among National Health Service Patients: Longitudinal Observational Study. <i>JMIR Public Health and Surveillance</i> , 2021, 7, e30460.	1.2	7
144	Respiratory-related death in individuals with incident asthma and COPD: a competing risk analysis. <i>BMC Pulmonary Medicine</i> , 2022, 22, 28.	0.8	7

#	ARTICLE	IF	CITATIONS
145	No association between exacerbation frequency and stroke in patients with COPD. <i>International Journal of COPD</i> , 2016, 11, 217.	0.9	6
146	Real-world effects of medications for chronic obstructive pulmonary disease: protocol for a UK population-based non-interventional cohort study with validation against randomised trial results. <i>BMJ Open</i> , 2018, 8, e019475.	0.8	6
147	Outcome measures in a combined exercise rehabilitation programme for adults with COPD and chronic heart failure: A preliminary stakeholder consensus event. <i>Chronic Respiratory Disease</i> , 2019, 16, 147997311986795.	1.0	6
148	Clinical profile of predefined asthma phenotypes in a large cohort of UK primary care patients (Clinical Practice Research Datalink). <i>Journal of Asthma and Allergy</i> , 2019, Volume 12, 7-19.	1.5	6
149	An observational cohort study of exercise and education for people with chronic obstructive pulmonary disease not meeting criteria for formal pulmonary rehabilitation programmes. <i>Chronic Respiratory Disease</i> , 2019, 16, 147997311983828.	1.0	6
150	Prediction of five-year mortality after COPD diagnosis using primary care records. <i>PLoS ONE</i> , 2020, 15, e0236011.	1.1	6
151	<p>Prescribing Pathways to Triple Therapy: A Retrospective Observational Study of Adults with Chronic Obstructive Pulmonary Disease in the UK</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 3261-3271.	0.9	6
152	Feasibility of using Clinical Practice Research Datalink data to identify patients with chronic obstructive pulmonary disease to enrol into real-world trials. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 472-481.	0.9	6
153	Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial. <i>International Journal of COPD</i> , 2021, Volume 16, 841-851.	0.9	6
154	Mortality Risk in Patients With Adrenal Insufficiency Using Prednisolone or Hydrocortisone: A Retrospective Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 2242-2251.	1.8	6
155	Predicting Future Health Risk in COPD: Differential Impact of Disease-Specific and Multi-Morbidity-Based Risk Stratification. <i>International Journal of COPD</i> , 2021, Volume 16, 1741-1754.	0.9	6
156	Inhaled therapies for chronic obstructive pulmonary disease: a systematic review and meta-analysis. <i>BMJ Open</i> , 2020, 10, e036455.	0.8	6
157	Systemic manifestations of chronic obstructive pulmonary disease. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2015, 76, 324-329.	0.2	5
158	Asthma and lung cancer, after accounting for co-occurring respiratory diseases and allergic conditions: a systematic review protocol. <i>BMJ Open</i> , 2017, 7, e013637.	0.8	5
159	Association between childhood allergic diseases, educational attainment and occupational status in later life: systematic review protocol. <i>BMJ Open</i> , 2017, 7, e017245.	0.8	5
160	National Asthma and COPD Audit Programme and the NHS Long Term Plan. <i>Lancet Respiratory Medicine</i> , 2019, 7, 841.	5.2	5
161	Does pay-for-performance improve patient outcomes in acute exacerbation of COPD admissions?. <i>Thorax</i> , 2022, 77, 239-246.	2.7	5
162	Under-recognition of heart failure in patients with atrial fibrillation and the impact of gender: a UK population-based cohort study. <i>BMC Medicine</i> , 2021, 19, 179.	2.3	5

#	ARTICLE	IF	CITATIONS
163	Inhaled Corticosteroid Withdrawal and Change in Lung Function in Primary Care Patients with Chronic Obstructive Pulmonary Disease in England. <i>Annals of the American Thoracic Society</i> , 2022, 19, 1834-1841.	1.5	5
164	Code sets for respiratory symptoms in electronic health records research: a systematic review protocol. <i>BMJ Open</i> , 2019, 9, e025965.	0.8	4
165	Protocol for a systematic literature review and network meta-analysis of the clinical benefit of inhaled maintenance therapies in chronic obstructive pulmonary disease. <i>BMJ Open</i> , 2019, 9, e025048.	0.8	4
166	Concordance in the recording of stroke across UK primary and secondary care datasets: a population-based cohort study. <i>BJGP Open</i> , 2021, 5, BJGPO.2020.0117.	0.9	4
167	NEWS2 as an Objective Assessment of Hospitalised COPD Exacerbation Severity. <i>International Journal of COPD</i> , 2022, Volume 17, 763-772.	0.9	4
168	Impact of COPD and asthma on in-hospital mortality and management of patients with heart failure in England and Wales: an observational analysis. <i>BMJ Open</i> , 2022, 12, e059122.	0.8	4
169	Self-reported symptoms of chronic cough and breathlessness in working-age men in the city of Izhevsk, Russia: associations with cardiovascular disease risk factors and comorbidities. <i>BMJ Open Respiratory Research</i> , 2015, 2, e000104.	1.2	3
170	COPD exacerbations: transforming outcomes through research. <i>Lancet Respiratory Medicine</i> , 2018, 6, 172-174.	5.2	3
171	Hospitalisation and mortality outcomes of patients with comorbid COPD and heart failure: a systematic review protocol. <i>BMJ Open</i> , 2018, 8, e023058.	0.8	3
172	Unscheduled hospital contacts after inpatient discharge: A national observational study of COPD and heart failure patients in England. <i>PLoS ONE</i> , 2019, 14, e0218128.	1.1	3
173	Chronic Obstructive Pulmonary Disease (COPD) in Population Studies in Russia and Norway: Comparison of Prevalence, Awareness and Management. <i>International Journal of COPD</i> , 2021, Volume 16, 1353-1368.	0.9	3
174	Clinical and methodological considerations when interpreting meta-analyses of beta-blocker use in patients with chronic obstructive pulmonary disease. <i>European Heart Journal</i> , 2021, 42, 3407-3408.	1.0	3
175	Genome-wide association study of susceptibility to hospitalised respiratory infections. <i>Wellcome Open Research</i> , 0, 6, 290.	0.9	3
176	Evaluating a Cox marginal structural model to assess the comparative effectiveness of inhaled corticosteroids versus no inhaled corticosteroid treatment in chronic obstructive pulmonary disease. <i>Annals of Epidemiology</i> , 2022, 67, 19-28.	0.9	3
177	Cost-consequence analysis of COPD treatment according to NICE and GOLD recommendations compared with current clinical practice in the UK. <i>BMJ Open</i> , 2022, 12, e059158.	0.8	3
178	Prognostic variables and scores identifying the last year of life in COPD: a systematic review protocol. <i>BMJ Open</i> , 2016, 6, e011677.	0.8	2
179	Asthma hospitalisations and air pollution. <i>Thorax</i> , 2016, 71, 1076-1077.	2.7	2
180	Effect of beta-blocker therapy on clinical outcomes, safety, health-related quality of life and functional capacity in patients with chronic obstructive pulmonary disease (COPD): a protocol for a systematic literature review and meta-analysis with multiple treatment comparison. <i>BMJ Open</i> , 2018, 8, e024736.	0.8	2

#	ARTICLE	IF	CITATIONS
181	Can't see the wood for the trees: confounders, colliders and causal inference - a clinician's approach. <i>Thorax</i> , 2019, 74, 321-322.	2.7	2
182	Using routine health data for research: the devil is in the detail. <i>Thorax</i> , 2020, 75, 714-715.	2.7	2
183	Validation of acute exacerbation of chronic obstructive pulmonary disease (COPD) recording in electronic health records: a systematic review protocol. <i>BMJ Open</i> , 2020, 10, e032467.	0.8	2
184	Improving outcomes for children with asthma: role of national audit. <i>Archives of Disease in Childhood</i> , 2020, 105, 919-920.	1.0	2
185	Identifying COPD in routinely collected electronic health records: a systematic scoping review. <i>ERJ Open Research</i> , 2021, 7, 00167-2021.	1.1	2
186	Preliminary results from the COPE study using primary-care electronic health records and environmental modelling to examine COPD exacerbations. <i>British Journal of General Practice</i> , 2018, 68, bjgp18X696749.	0.7	2
187	EFFECTIVENESS OF COPD MAINTENANCE THERAPY WITH LAMA/LABA VS LAMA/LABA/ICS IN A UNITED STATES CLAIMS DATABASE. <i>Chest</i> , 2021, 160, A1863-A1864.	0.4	2
188	Characteristics of patients in platform C19, a COVID-19 research database combining primary care electronic health record and patient reported information. <i>PLoS ONE</i> , 2021, 16, e0258689.	1.1	2
189	Deriving a Standardised Recommended Respiratory Disease Codelist Repository for Future Research. <i>Journal of Pragmatic and Observational Research</i> , 2022, Volume 13, 1-8.	1.1	2
190	New insights into the optimal management of COPD: Extracts from CHEST 2021 annual meeting (October 17-20, 2021). <i>Expert Review of Respiratory Medicine</i> , 2022, , .	1.0	2
191	Left-sided heart failure burden and mortality in idiopathic pulmonary fibrosis: a population-based study. <i>BMC Pulmonary Medicine</i> , 2022, 22, 190.	0.8	2
192	Assessment of the burden of disease for patients with peripheral artery disease undergoing revascularization in England. <i>Vascular Medicine</i> , 2022, 27, 440-449.	0.8	2
193	Impact of new home oxygen service on respiratory units. <i>Thorax</i> , 2006, 61, 830-830.	2.7	1
194	Weighing up risk factors for pneumonia: the role of mental illness and benzodiazepine use. <i>Thorax</i> , 2013, 68, 121-122.	2.7	1
195	Are clinical risk scores for COPD useful?. <i>BMJ Open Respiratory Research</i> , 2015, 2, e000072.	1.2	1
196	Smoking cessation and COPD: further evidence is more necessary than ever. <i>European Respiratory Journal</i> , 2017, 49, 1700466.	3.1	1
197	Chronic obstructive pulmonary disease and myocardial infarction: when will we get our act together?. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019, 6, 1-2.	1.8	1
198	The Utilization and Safety of Umeclidinium and Umeclidinium/Milanterol in UK Primary Care: A Retrospective Cohort Study. <i>International Journal of COPD</i> , 2021, Volume 16, 629-642.	0.9	1

#	ARTICLE	IF	CITATIONS
199	COPD: still an unpredictable journey. <i>European Respiratory Journal</i> , 2021, 57, 2002933.	3.1	1
200	COPD Epidemiology. , 2022, , 515-525.		1
201	GRACE scores in COPD patients with acute coronary syndromes: Performance and impact on secondary prevention. , 2015, , .		1
202	The challenge of palliative care. , 0, , 297-322.		1
203	The Air We Breathe: Effect of Environmental Exposures on COPD. <i>Tanaffos</i> , 2017, 16, S14-S15.	0.5	1
204	Call for reviewers for journal club in <i>Thorax</i> . <i>Thorax</i> , 2012, 67, 116-116.	2.7	0
205	Pneumonia in the Non-HIV-Infected Immunocompromised Patient. , 2012, , 330-345.		0
206	Keeping a chest™ of the literature. <i>Thorax</i> , 2013, 68, 610-610.	2.7	0
207	CT-diagnosed emphysema and lung cancer mortality: novel association or old news?. <i>Thorax</i> , 2016, 71, 583-584.	2.7	0
208	Measuring cardiovascular risk in COPD; child™s play or MENSA?. <i>Chronic Respiratory Disease</i> , 2016, 13, 209-210.	1.0	0
209	Thinking outside the lungs: other™ risk factors for pneumonia hospitalisation. <i>Thorax</i> , 2017, 72, 596.2-597.	2.7	0
210	Cottage by the sea or house above the trees: which is better for my lungs?. <i>Thorax</i> , 2018, 73, 1103-1104.	2.7	0
211	Response. <i>Chest</i> , 2018, 153, 1282-1283.	0.4	0
212	Reply to letter to the editor by Dr. Jolobe. <i>International Journal of Cardiology</i> , 2019, 292, 161.	0.8	0
213	Methodologic Issues With Comparative Effectiveness Study on LAMA-LABA-ICS vs LAMA-LABA for the Treatment of COPD in the Clinical Practice Research Datalink. <i>Chest</i> , 2020, 158, 831-832.	0.4	0
214	The Role of Individual and Neighborhood Factors on Racial Disparity in Respiratory Outcomes. Won™t You Be My Neighbor?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 939-940.	2.5	0
215	Development and Validation of a Method to Estimate COPD Severity in Multiple Datasets: A Retrospective Study. <i>Pulmonary Therapy</i> , 2021, 7, 119-132.	1.1	0
216	Addressing a system failure to diagnose COPD and asthma. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 814-816.	5.2	0

#	ARTICLE	IF	CITATIONS
217	Medications for chronic obstructive pulmonary disease: a historical non-interventional cohort study with validation against RCT results. <i>Health Technology Assessment</i> , 2021, 25, 1-70.	1.3	0
218	Challenges and Pitfalls of Using Repeat Spirometry Recordings in Routine Primary Care Data to Measure FEV1 Decline in a COPD Population. <i>Journal of Pragmatic and Observational Research</i> , 2021, Volume 12, 119-130.	1.1	0
219	Author's reply to Wolstenholme and Sanfilippo and colleagues. <i>BMJ</i> , The, 2014, 348, g1132-g1132.	3.0	0
220	Title is missing!. , 2020, 17, e1003145.		0
221	Title is missing!. , 2020, 17, e1003145.		0
222	Title is missing!. , 2020, 17, e1003145.		0
223	Title is missing!. , 2020, 17, e1003145.		0
224	Title is missing!. , 2020, 17, e1003145.		0